Greenleaf Trust Buys 623 Shares of Hologic, Inc. (NASDAQ:HOLX)

Greenleaf Trust grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 13.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,147 shares of the medical equipment provider’s stock after buying an additional 623 shares during the period. Greenleaf Trust’s holdings in Hologic were worth $368,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Federated Hermes Inc. raised its position in shares of Hologic by 16.9% during the fourth quarter. Federated Hermes Inc. now owns 9,355 shares of the medical equipment provider’s stock valued at $668,000 after buying an additional 1,355 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt increased its position in Hologic by 145.3% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 790 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 468 shares during the last quarter. Wealth Alliance increased its position in Hologic by 3.9% in the fourth quarter. Wealth Alliance now owns 5,739 shares of the medical equipment provider’s stock worth $410,000 after purchasing an additional 217 shares during the last quarter. Mackenzie Financial Corp increased its position in Hologic by 17.3% in the fourth quarter. Mackenzie Financial Corp now owns 76,722 shares of the medical equipment provider’s stock worth $5,482,000 after purchasing an additional 11,308 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. increased its position in Hologic by 2.4% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 26,679 shares of the medical equipment provider’s stock worth $1,906,000 after purchasing an additional 637 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Trading Up 1.3 %

Shares of HOLX opened at $77.19 on Wednesday. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $87.88. The company has a market cap of $18.12 billion, a P/E ratio of 36.58, a P/E/G ratio of 2.55 and a beta of 1.00. The company has a current ratio of 3.89, a quick ratio of 3.18 and a debt-to-equity ratio of 0.55. The company’s fifty day simple moving average is $75.87 and its 200-day simple moving average is $72.69.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $989.32 million. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.07 earnings per share. As a group, analysts expect that Hologic, Inc. will post 4.01 EPS for the current year.

Insider Transactions at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now directly owns 48,611 shares in the company, valued at $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,846 shares of company stock worth $2,473,443. Insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of several research reports. Evercore ISI boosted their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. UBS Group boosted their price target on shares of Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Finally, Raymond James boosted their price objective on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. Six research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $87.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.